A Case Study of Medical System’s Supply Chain Model for In vitro Diagnostic Device

碩士 === 東吳大學 === 企業管理學系 === 93 === This study primarily will benefit many women with the early detection of various cancers, which is an important concept of the preventive medicine, particularly on the cervical cancer. By using the case-study method, this study has been focused on the discussion of...

Full description

Bibliographic Details
Main Authors: Ta-Te Huang, 黃大德
Other Authors: Shong-iee Su
Format: Others
Language:zh-TW
Published: 2005
Online Access:http://ndltd.ncl.edu.tw/handle/40198511100578470470
Description
Summary:碩士 === 東吳大學 === 企業管理學系 === 93 === This study primarily will benefit many women with the early detection of various cancers, which is an important concept of the preventive medicine, particularly on the cervical cancer. By using the case-study method, this study has been focused on the discussion of the supply chain for in vitro diagnostic devices. Starting from the analysis of business processes of the supply chain in a local company, it was found that current business models of research, development, production, marketing, and the services of end customers have been processed from many divergent business supply chains to a convergent business supply chain. On the other hand, the competitive status of products manufactured by this local company was thoroughly discussed by using the Five Forces Analysis method. By using the deep interview with internal members, including members of the business activity of the supply chain, and external experts such as evaluation centers for medical devices and consulting companies, the result was summarized and became the scheme for companies of in vitro diagnostic devices on how to expand the scale of the operation. No matter products development and their commercialization on the frontline of the supply chain or the management of the backup customer service, this scheme is intended to help the development of in vitro diagnostic devices to figure out an experienced and feasible direction for many potential participants in the realm of biotechnology. The last but not the least, this scheme may shorten the time between the product development and its commercialization on the market, as well as accelerate the business flow of the supply chain for the biotechnology industry.